Novo Nordisk’s Obesity Drug Breakthrough: 22% Weight Loss at Week 36 Boosts Stock by 11%

Significant Weight Loss:
Novo Nordisk's next-gen obesity drug, amycretin, has shown a 22% weight loss in patients after 36 weeks of weekly injections2 3 5.

Stock Performance:
The company's stock surged by 11% following the announcement of these promising trial results2 4 5.

Semaglutide Trial Success:
Novo Nordisk also reported outstanding results from the STEP UP trial for semaglutide 7.2mg, demonstrating substantial weight loss and a favorable safety profile1 4.

Analyst Reactions:
Guggenheim and BofA analysts have expressed optimism about Novo Nordisk's future, with Guggenheim raising its price target to DKK 798 and maintaining a "Buy" rating1 4.

Market Dynamics:
The company faces challenges such as patent expirations and competitive pressures, but analysts see potential buying opportunities and long-term strategic resilience1 4.

U.S. Medicare Price Negotiations:
Novo Nordisk's key products, including Ozempic and Wegovy, are part of U.S. Medicare's pricing discussions for 2027, which could impact their pricing and accessibility1 4.